Gatipotuzumab

Last updated July 17, 2025

Gatipotuzumab
Monoclonal antibody
Type	Whole antibody
Source	Humanized (from mouse)
Target	tumor specific glycosylation of MUC1
Clinical data
Other names	PankoMab-GEX, anti-TA-MUC1
ATC code	None
Identifiers
CAS Number	1264737-26-9 ^Y
ChemSpider	none
UNII	85V55ZLV2Z

Gatipotuzumab is a humanized monoclonal antibody recognizing the tumor-specific epitope of mucin-1 (TA-MUC1), enabling it to differentiate between tumor MUC1 and non-tumor MUC1 epitopes.^[1] Gatipotuzumab is being developed by Glycotope GMBH ^[2] and is undergoing a phase II clinical trial for ovarian cancer.^[3]

References

↑ "Gatipotuzumab". Drug Dictionary. National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services.
↑ "Gatipotuzumab – Our first-in-class GlycoBody against the novel tumor-specific TA-MUC1 epitope". Glycotope GmbH.
↑ Clinical trial number NCT01899599 for "PankoMab-GEX™ Versus Placebo as Maintenance Therapy in Advanced Ovarian Cancer " at ClinicalTrials.gov

External links

"Gatipotuzumab". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on December 9, 2023.

Monoclonal antibodies for tumors

Tumor

Human	Adecatumumab ^§ Amivantamab Ascrinvacumab ^§ Atezolizumab (+hyaluronidase) Balstilimab ^† Botensilimab Cixutumumab ^§ Conatumumab ^§ Cosibelimab Daratumumab Drozitumab ^§ Duligotumab ^§ Dusigitumab ^§ Enfortumab vedotin Enoticumab ^§ Figitumumab ^§ Flanvotumab ^§ Ganitumab ^† Glembatumumab vedotin ^† Intetumumab ^§ Ipilimumab Iratumumab ^§ Istiratumab Icrucumab ^§ Lexatumumab ^§ Linvoseltamab Lucatumumab ^§ Mapatumumab ^§ Narnatumab ^§ Necitumumab Nesvacumab ^§ Nivolumab ^# (+hyaluronidase, +relatlimab) Ofatumumab Olaratumab ^† Panitumumab Patritumab ^§ Pembrolizumab ^# Pritumumab ^§ Radretumab ^§ Ramucirumab Rilotumumab ^† Robatumumab ^§ Seribantumab ^§ Sugemalimab Tarextumab ^§ Tisotumab vedotin Teprotumumab ^† Tovetumab ^§ Vantictumab ^§ Votumumab ^§ Zalutumumab ^†
Mouse	Abagovomab Altumomab pentetate Anatumomab mafenatox Arcitumomab Bectumomab Blinatumomab Capromab pendetide Detumomab Edrecolomab Ibritumomab tiuxetan Igovomab Lilotomab Minretumomab Mitumomab Nacolomab tafenatox Moxetumomab pasudotox Naptumomab estafenatox Oregovomab Pemtumomab ^† Racotumomab Satumomab pendetide Solitomab Taplitumomab paptox Nofetumomab merpentan Pintumomab Tenatumomab Tositumomab
Chimeric	Amatuximab ^§ Bavituximab ^§ Brentuximab vedotin Carotuximab ^† Cetuximab Derlotuximab biotin ^§ Dinutuximab Ecromeximab ^§ Ensituximab ^§ Futuximab ^§ Girentuximab ^† Indatuximab ravtansine ^§ Isatuximab Loncastuximab tesirine Margetuximab Mirvetuximab soravtansine Rituximab ^# Siltuximab Ublituximab Zolbetuximab
Humanized	Abituzumab ^§ Alemtuzumab Axatilimab Belantamab mafodotin Bevacizumab Bivatuzumab mertansine ^§ Brontictuzumab ^§ Cantuzumab mertansine ^§ Cantuzumab ravtansine ^§ Cirmtuzumab Citatuzumab bogatox ^§ Clivatuzumab tetraxetan Cofetuzumab pelidotin Dacetuzumab ^§ Demcizumab ^§ Dalotuzumab ^§ Datopotamab deruxtecan Denintuzumab mafodotin ^§ Elotuzumab Emactuzumab Emibetuzumab ^§ Enoblituzumab ^§ Epcoritamab Etaracizumab ^§ Farletuzumab ^§ Ficlatuzumab ^§ Flotetuzumab ^§ Gemtuzumab ozogamicin Glofitamab Imgatuzumab ^§ Inotuzumab ozogamicin Labetuzumab ^§ Lifastuzumab vedotin ^§ Lintuzumab ^§ Lorvotuzumab mertansine ^§ Lumretuzumab ^§ Matuzumab ^§ Milatuzumab ^§ Naxitamab Nimotuzumab ^† Obinutuzumab Ocaratuzumab ^§ Odronextamab Otlertuzumab ^§ Onartuzumab ^§ Oportuzumab monatox ^† Parsatuzumab ^§ Penpulimab Pertuzumab Pinatuzumab vedotin ^§ Polatuzumab vedotin Rosmantuzumab Rovalpituzumab tesirine ^† Sacituzumab govitecan Sibrotuzumab ^§ Simtuzumab ^§ Sofituzumab vedotin ^§ Tacatuzumab tetraxetan ^§ Tigatuzumab ^§ Trastuzumab ^# (+deruxtecan / +emtansine) Tucotuzumab celmoleukin ^§ Vandortuzumab vedotin ^§ Vanucizumab ^§ Veltuzumab ^§ Vorsetuzumab mafodotin ^§ Zenocutuzumab
Rat/mouse hybrid	Catumaxomab Ertumaxomab ^§
Chimeric + humanized	Depatuxizumab mafodotin ^† Duvortuxizumab Ontuxizumab ^§

^# WHO-EM
^‡ Withdrawn from market
Clinical trials:
- ^† Phase III
- ^§Never to phase III

This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it.

This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.